Business
Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool
About this update from Tempus Ai, Inc.
[{"type":"text","content":"\nPeer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data\n\n\n ALISO VIEJO, Calif.--(BUSINESS WIRE)--\nAmbry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. The study, “Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk for Hereditary Cancer,” demonstrated that the CARE program accurately interprets NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1,2 with 99.5% accuracy, reinforcing its effectiveness as a digital risk assessment tool for identifying patients who may benefit from hereditary cancer-focused genetic testing and personalized care.\n\n\nApproximately 5% of individuals have a mutation in a cancer predisposition gene, yet most are unaware.3 NCCN Guidelines® are a trusted source for hereditary cancer testing criteria, but their complexity and frequent updates may make them difficult for non-specialist clinicians and digital health tools to apply effectively. CARE addresses this gap by streamlining the hereditary cancer risk assessment process.\n\n\n“The validation of CARE’s accuracy reinforces what we’ve experienced at HCA Healthcare’s Sarah Cannon Cancer Network – that, in addition to being well received by our patients, CARE’s assessment can reliably identify patients who need genetic services,” said Dr. Dax Kurbegov, Vice President and Physician-In-Chief of Clinical Programs, HCA Healthcare’s Sarah Cannon Cancer Network. “With demonstrated 99.5% accuracy in applying clinical guidelines, we can confidently scale hereditary cancer risk assessment across our community hospitals, ensuring more patients have access to potentially life-saving genetic insights.”\n\n\nThe Ambry CARE Program® leverages digital health solutions to enable health systems to stratify patients by cancer risks, driving personalized, proactive care. Its HIPAA-compliant application integrates with electronic health records and collects medical and family history directl...